Table 3.

Association between sarcopenia and polypharmacy

	Total cohort		Younger adults		Older adults
	OR (95% CI)	P‐value	OR (95% CI)	P‐value	OR (95% CI)	P‐value
Polypharmacy unadjusted	2.20 (1.23–3.94)	0.008	1.78 (0.56–5.62)	0.327	2.10 (1.04–4.23)	0.039
Polypharmacy adjusted for age	1.93 (1.06–3.51)	0.032	1.79 (0.56–5.66)	0.916	1.97 (0.97–4.01)	0.061
Polypharmacy adjusted for age and sex	2.01 (1.10–3.70)	0.024	1.91 (0.59–6.12)	0.279	2.03 (0.99–4.15)	0.053
Polypharmacy adjusted for age, sex, and BMI	2.02 (1.06–3.84)	0.032	2.17 (0.63–7.50)	0.221	1.95 (0.91–4.15)	0.085
Polypharmacy adjusted for age, sex, BMI, and etiology	2.10 (1.09–4.04)	0.026	2.12 (0.60–7.56)	0.245	2.23 (1.01–4.90)	0.046
Polypharmacy adjusted for age, sex, BMI, etiology, and MELD score	2.11 (1.07–4.17)	0.032	1.56 (0.40–6.01)	0.522	2.62 (1.14–6.02)	0.023

Abbreviations: BMI, body mass index; CI, confidence interval; MELD, Model for End‐Stage Liver Disease; OR, odds ratio.